Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
- PMID: 35887653
- PMCID: PMC9325299
- DOI: 10.3390/jpm12071156
Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation
Abstract
Sickle cell disease (SCD) is considered a rare disease in Germany. Due to the increasing prevalence, the acute and chronic morbidities associated with the disease and the sharp increase in the mortality rate of young adults, a need-based transition structure for patients with SCD in Germany is explicitly required. This is the first multicenter German consensus statement addressing the importance of implementing a standardized transition guideline that allows adolescents and young adults to safely transition from pediatric to adult care. Early identification of medical needs and intervention remains important in the context of chronic diseases. Effective measures can improve health care in general, as they lead to a reduction in disease and the consequential economic burden. It is noteworthy that improving structural barriers remains a key challenge even in highly developed countries such as Germany. Inclusion of these transition services for patients with SCD into the regular care of chronically ill adolescents and young adults should be ensured, as well as the coverage of costs associated with a structured transition process.
Keywords: Germany; child blood non-malignant diseases; ethics issues and patient-oriented perspectives; patient registries and standardization; sickle cell disease (SCD); transition.
Conflict of interest statement
Ferras Alashkar received consultancy fees and honoraria from Novartis, bluebird bio, Agios, GBT and BMS/Celgene; Carmen Aramayo-Singelmann received consultancy fees and honoraria from Novartis, Agios, GBT, and BMS/Celgene; Janine Böll received consultancy fees and honoraria from Novartis, BMS/Celgene, bluebird bio and GBT; Annette Hofere received consultancy fees and honoraria from Novartis; Andrea Jarisch received consultancy fees and honoraria from Novartis and bluebird bio; Haytham Kamal received consultancy fees and honoraria from Novartis; Lena Oevermann received consultancy fees and honoraria from Novartis, Vertex Pharmaceuticals, GBT and AddMedica; Michaela Schwarz received consultancy fees and honoraria from Novartis; Holger Cario received consultancy fees and honoraria from Novartis, GBT, Vertex, bluebird Bio, Agios, BMS/Celgene and Chiesi. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
-
- Gesellschaft für Transitionsmedizin S3-Leitlinie: Transition von der Pädiatrie in die Erwachsenenmedizin. Version 1.1 vom 22 April 2021. [(accessed on 16 March 2022)]. Available online: https://www.awmf.org/leitlinien/detail/ll/186-001.html.
Grants and funding
LinkOut - more resources
Full Text Sources
